黄素对放射性皮肤炎的治疗功效:一个系统的审查
Hossein Abdeahad1,2, Nikoo Saeedi3,2, Afsane Bahrami4,2
1Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Avicenna journal of phytomedicine
|August 1, 2024
概括
黄素 (CUR) 可能降低放射性皮炎 (RD) 的强度,这是放射治疗 (RT) 的常见副作用. 需要进一步的研究来确认CUR.
科学领域:
- 在瘤学瘤学.
- 皮肤病学 皮肤病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 放射性皮炎 (RD) 是放射治疗 (RT) 的常见不良事件.
- 目前对RD的治疗方案缺乏共识.
- 黄 (CUR) 是一种来自黄的天然多,具有低毒性.
研究的目的:
- 系统地审查CUR在预防和治疗RD中的有效性.
- 探索CUR在支持性癌症护理中的潜力.
主要方法:
- 在多个数据库 (Cochrane,PubMed,Scopus,科学网,MEDLINE,EMBASE) 的系统文献审查.
- 包括5项研究:3项RCT,1项试点研究,1项受控研究.
- 研究的重点是乳腺癌,头癌和其他癌症类型.
主要成果:
- 四项研究表明,CUR应用降低了放射性皮肤炎的强度.
- 一项研究发现,CUR对放射性皮肤炎没有显著的影响.
- 证据表明CUR在癌症支持性护理中的临床价值.
结论:
- 实质性证据支持CUR在R&D管理中的作用.
- 需要进一步进行大规模的前性试验.
- 需要确定RD的最佳补充形式和CUR的剂量.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
149
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
149
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
110
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
110
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
124
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
124


